- Theravance failed 3 trials last year.
- There was a major restructuring and change of focus.
- A small revenue stream from YUPELRI is its only positive, but that doesn't justify the valuation.
For further details see:
Theravance: All-Round FailureFor further details see:
Theravance: All-Round FailureMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 08:00:00 ET GSK (NYSE: GSK) , a global healthcare powerhouse, has been on a transformative journey since CEO Emma Walmsley took the helm in 2017. Despite its shares badly underperforming the S&P 500 under her first few years as CEO (see graph below), Walmsley's am...
2024-07-11 23:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
GSK supports annual flu immunization by getting FLULAVAL and FLUARIX to patients in advance of flu season GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2024-25 fl...